Physician profile
Nathan E Tobey
NPI 1306188479
$2,347.93
in general payments reported to CMS, 2019-2025
31 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.80 · 2020: $197 · 2021: $372 · 2022: $666 · 2023: $406 · 2024: $270 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $369.02 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $310.12 | 2021-2024 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $206.63 | 2020-2024 | Fasenra, Imfinzi, Airsupra |
| Intuitive Surgical, INC. | $181.32 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.60 | 2021-2025 | Gilotrif, Ofev |
| Abbvie INC. | $151.81 | 2021-2022 | |
| Insmed, INC. | $127.71 | 2022-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $101.63 | 2019-2025 | Dupixent |
| Livanova USA, INC. | $88.85 | 2022 | |
| Jazz Pharmaceuticals INC. | $66.40 | 2021-2025 | |
| Lilly USA, LLC | $64.42 | 2021-2025 | Retevmo, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $48.59 | 2020-2024 | Fruzaqla |
| Csl Behring | $45.44 | 2025 | Kcentra |
| Grifols USA, LLC | $41.76 | 2025 | Prolastin-C Liquid |
| Allergan, INC. | $37.50 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $32.89 | 2022 | |
| Genentech USA, INC. | $31.41 | 2022-2024 | Alecensa, Tecentriq |
| Emd Serono, INC. | $30.39 | 2020 | |
| Circassia INC. | $27.68 | 2019-2020 | |
| United Therapeutics Corporation | $25.75 | 2025 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $21.56 | 2020 | |
| Janssen Biotech, INC. | $21.18 | 2024 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $19.88 | 2024 | Ultomiris |
| Advanced Respiratory, INC | $19.46 | 2021 | |
| Genzyme Corporation | $18.38 | 2024 | |
| Abiomed | $16.65 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $14.25 | 2025 | Opsynvi |
| Seagen INC. | $12.46 | 2022 | |
| Intercept Pharmaceuticals, INC. | $11.58 | 2021 | |
| Veran Medical Technologies, INC. | $11.47 | 2020 | |
| Novo Nordisk INC | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Tobey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.